NCT02610426 Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
| NCT ID | NCT02610426 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Breast Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 162 participants |
| Start Date | 2014-03-25 |
| Primary Completion | 2100-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 162 participants in total. It began in 2014-03-25 with a primary completion date of 2100-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.
Eligibility Criteria
Inclusion Criteria: * European American patients with DNA available * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls
Contact & Investigator
Bryan P Schneider
PRINCIPAL INVESTIGATOR
Eastern Cooperative Oncology Group
Frequently Asked Questions
Who can join the NCT02610426 clinical trial?
This trial is open to participants of all sexes, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02610426 currently recruiting?
Yes, NCT02610426 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Cancer Institute (NCI) to inquire about joining.
Where is the NCT02610426 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT02610426 clinical trial?
NCT02610426 is sponsored by National Cancer Institute (NCI). The principal investigator is Bryan P Schneider at Eastern Cooperative Oncology Group. The trial plans to enroll 162 participants.